Regenxbio Inc is a biotechnology company focused on advancing the field of gene therapy for the treatment of rare and debilitating diseases. The company specializes in developing innovative therapies that utilize its proprietary AAV (adeno-associated virus) gene delivery technology, which aims to correct genetic defects and restore normal function at the cellular level. Regenxbio is committed to addressing unmet medical needs through its robust pipeline of product candidates, targeting various conditions, including inherited retinal diseases and neurodegenerative disorders. By harnessing the power of gene therapy, Regenxbio seeks to transform treatment options and improve the quality of life for patients.
PALM BEACH, Fla., Sept. 04, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The SARS-CoV-2, literally affected the whole world in these past years and has increased a global search for therapies and treatments. A report from Transparency Market Research said that: “the emergence of new variants of coronavirus will boost COVID-19 therapeutics market growth. Demand for drugs that can effectively treat new strains of the virus is likely to be significantly high, as these new variants may be less susceptible to existing therapeutics. This is projected to boost the COVID-19 therapeutics market size, as pharmaceutical companies race to develop new drugs and treatments to address these new variants. Even after the pandemic is under control, there would still be a need for treatments and therapies to help those who have been affected by the virus, including those with long-term effects. This is anticipated to continue to drive COVID-19 therapeutics market demand. Additionally, emergence of new variants of the virus and the possibility of future outbreaks are anticipated to prompt governments and private organizations to be better prepared for future pandemics.” Active companies in the biotech industry this week include Sunshine Biopharma Inc. (NASDAQ: SBFM), Novavax, Inc. (NASDAQ: NVAX), REGENXBIO Inc. (NASDAQ: RGNX), BIONTECH SE (NASDAQ: BNTX), Abbvie (NYSE: ABBV).
Clearside Biomedical pioneers suprachoroidal drug delivery for precise, effective treatment of retinal diseases. Oppenheimer rates CLSD Outperform with a $5 target, citing its innovative SCS Microinjector and strategic partnerships.
The FDA has approved Sarepta Therapeutics' Elevidys for treating Duchenne muscular dystrophy in patients aged 4 and older with specific DMD gene mutations.
